InMed Pharmaceuticals gets Nasdaq equity deficiency notice
InMed Pharmaceuticals received a Nasdaq equity deficiency notice stating its shareholders’ equity is below the $2.5M minimum. The company expects to regain compliance after its planned Mentari merger.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.